Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
Stopped Portfolio reprioritization
Conditions
- Chronic Inflammatory Disease
Interventions
- DRUG: CBS001
- DRUG: Placebo
Sponsor
Capella Bioscience Ltd
Collaborators